Tesamorelin vs CJC-1295 (No DAC)
How do Tesamorelin and CJC-1295 (No DAC) compare for Growth Hormone Axis research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
Tesamorelin
CJC-1295 (No DAC)
Which fits which research target?
Both Tesamorelin and CJC-1295 (No DAC) sit within Growth Hormone Axis research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.
What the research shows
Tesamorelin
CJC-1295 (No DAC)
Compare prices across EU suppliers
Compare Tesamorelin across EU suppliers
11 EU vendors · COA · from €33.97
Compare CJC-1295 (No DAC) across EU suppliers
7 EU vendors · COA · from €23.89
Frequently asked questions
Is Tesamorelin or CJC-1295 (No DAC) better? ▾
Neither is an approved medicine, and “better” depends on the research target. Tesamorelin is most associated with Visceral fat reduction, while CJC-1295 (No DAC) is studied for Pulsatile GH release. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare Tesamorelin and CJC-1295 (No DAC)? ▾
Both are studied within Growth Hormone Axis research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, Tesamorelin or CJC-1295 (No DAC)? ▾
Prices vary by supplier, vial size and COA status. Tesamorelin is listed from €33.97 across 11 COA-verified EU vendors; CJC-1295 (No DAC) from €23.89 across 7. Open the price pages above to compare current listings — nobody pays us for placement.